Baseline characteristics of the study population according to dexrazoxane exposure
| Characteristic | No Dexrazoxane* (n=23) | Dexrazoxane* (n=62) | P† |
| Age, years | 13.1 (4.3) | 12.9 (5.3) | 0.86 |
| Female Sex | 8 (35) | 29 (47) | 0.32 |
| Race | |||
| White | 17 (74) | 47 (76) | 0.94 |
| Black | 4 (17) | 9 (14) | |
| Other | 2 (9) | 6 (10) | |
| Prior anthracycline exposure | 0 (0) | 1 (2) | 0.54 |
| Cancer Diagnosis | |||
| Ewing Sarcoma | 10 (44) | 24 (39) | 0.42 |
| Osteosarcoma | 9 (39) | 21 (34) | |
| Rhabdomyosarcoma | 0 (0) | 7 (11) | |
| Other soft tissue sarcoma | 4 (17) | 10 (16) | |
| Cancer Stage | |||
| Localised | 15 (65) | 48 (77) | 0.33 |
| Metastatic to lungs | 5 (22) | 6 (10) | |
| Widely metastatic | 3 (13) | 8 (13) | |
| Cumulative Doxorubicin Dose, mg/m2(median (IQR)) | 375 (375, 450) | 375 (375, 450) | 0.24‡ |
| Chest radiation exposure | 2 (9) | 5 (8) | 0.93 |
| Body surface area, m2 | 1.55 (0.46) | 1.46 (0.50) | 0.50 |
| Body mass index, kg/m2 | 20.8 (4.5) | 21.2 (6.0) | 0.76 |
| Systolic blood pressure, mmHg | 117 (13) | 113 (15) | 0.31 |
| Diastolic blood pressure, mmHg | 63 (10) | 64 (10) | 0.62 |
*P-values from two-sided t-tests or Pearson’s χ2 tests except where specified.
†P-value from Wilcoxon rank sum test.
‡Mean (SD) or number of subjects (% of total) except where specified.
IQR, IQR range.